# 2026年1月18日 - 专业文献速递

本期速递为您整理了最新的科研文献及AI评价，每一篇文献都包含了详细的元数据、原文摘要、中文翻译和AI的专业点评，敬请参考。

---

## 1. 作者更正：一种用于晚期结直肠癌多模态治疗的空心管状水凝胶海绵 (hydrospongel)

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41547844)
**期刊：** Nature communications
**PMID：** 41547844
**DOI：** 10.1038/s41467-026-68519-9

### 第一部分 原文与翻译

**英文原标题：** Author Correction: A hollow-tube-like hydrospongel for multimodal therapy of advanced colorectal cancer.

> **英文摘要：**
> No abstract available.

> **中文摘要：**
> 暂无摘要。

### 第二部分 AI 大师评价

本文献是针对发表在《自然-通讯》上关于空心管状水凝胶海绵用于晚期结直肠癌多模态治疗研究的作者更正。该研究原旨在开发一种结合宏观结构设计与生物材料功能化的系统，以实现针对复杂肿瘤环境的协同治疗。此类更正通涉及实验数据展示、作者署名信息或图表标注的精准化调整，反映了学术出版对严谨性的持续维护。尽管无具体摘要内容，但该条目对于追踪该生物材料在肿瘤治疗领域的最新校准数据具有关键参考价值。

---

## 2. 非人灵长类动物耳蜗的分子异质性

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41547823)
**期刊：** Nature communications
**PMID：** 41547823
**DOI：** 10.1038/s41467-026-68350-2

### 第一部分 原文与翻译

**英文原标题：** Molecular heterogeneity of the non-human primate cochlea.

> **英文摘要：**
> Unraveling the intricate composition and function of the cochlea is paramount to comprehending the mechanisms underlying sound perception and the pathogenesis of auditory disorders. The mammalian cochlea displays a highly organized structure, which contributes to the diversity and complexity of auditory processing. However, the cellular intricacies in non-human primates remain largely unexplored. In the present study, we employed high-throughput transcriptomic sequencing to profile over 36,701 nuclei across virtually all cochlear cell types in both juvenile and adult Macaca fascicularis at single-cell resolution. Our analysis unveiled remarkable heterogeneity both across and within cell types. Despite a largely conserved cellular composition of the cochlea between mouse and macaque species, glial cells exhibited substantial species-specific diversity, while hair cells and spiral ganglion neurons with specialized transcriptional programs were well-mapped onto their murine counterparts, underscoring the similarities that persist despite evolutionary divergence. Furthermore, we constructed a disease map associated with hearing loss, establishing this transcriptomic atlas of the macaque cochlea as an indispensable resource for future investigations in both human and non-human primates.

> **中文摘要：**
> 揭示耳蜗复杂的组成和功能对于理解声音感知的机制以及听力障碍的发病机理至关重要。哺乳动物耳蜗表现出高度组织化的结构，这有助于听觉处理的多样性和复杂性。然而，非人灵长类动物的细胞复杂性在很大程度上仍未被探索。在本研究中，我们采用高通量转录组测序，以单细胞分辨率对幼年和成年食蟹猴（Macaca fascicularis）中几乎所有耳蜗细胞类型的36,701多个细胞核进行了图谱绘制。我们的分析揭示了细胞类型之间和内部显著的异质性。尽管小鼠和猕猴物种之间的耳蜗细胞组成在很大程度上是保守的，但胶质细胞表现出显著的物种特异性多样性，而具有专门转录程序的毛细胞和螺旋神经节神经元与小鼠中的对应细胞能够很好地映射，强调了尽管存在进化差异，但仍保持着相似性。此外，我们构建了一个与听力损失相关的疾病图谱，将这一猕猴耳蜗转录组图谱确立为人类和非人灵长类动物未来研究不可或缺的资源。

### 第二部分 AI 大师评价

该研究利用单细胞转录组测序技术，首次绘制了食蟹猴耳蜗的高分辨率分子图谱，填补了非人灵长类听觉系统细胞层面的研究空白。研究揭示了猕猴与小鼠在耳蜗细胞组成上的高度保守性，同时也指出了胶质细胞中存在的显著种属特异性。通过构建听力损失相关的疾病图谱，该研究为人类听力障碍的病理机制研究和精准医疗开发提供了关键的生物学基础，具有重要的学术价值和临床指导意义。

---

## 3. 机械通气的机械功率：追踪损伤性成分

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41545894)
**期刊：** Critical care (London, England)
**PMID：** 41545894
**DOI：** 10.1186/s13054-025-05679-y

### 第一部分 原文与翻译

**英文原标题：** Mechanical power of ventilation: tracking the damaging component.

> **英文摘要：**
> Mechanical power has emerged as a unifying metric to quantify the risk of ventilator-induced lung injury (VILI), integrating multiple ventilatory parameters-such as tidal volume, airway pressures, respiratory rate, and inspiratory airflow-into a single measure of the mechanical energy delivered to the lungs. However, total mechanical power alone cannot fully predict the likelihood of injury, as the development of VILI depends not only on delivered energy but also on how this energy interacts with the lung's regional mechanical properties and its intrinsic vulnerability to stress. Critically, only externally measured inflation energy that exceeds one or more local alveolar stress thresholds-termed hazardous elastic power-is likely to contribute to lung damage. In this context, we propose a conceptual method to quantify this damaging component of mechanical power in relation to regional stress thresholds for injury. Once refined and validated, incorporating this approach into clinical practice could enhance individualized, lung-protective ventilation strategies by recognizing that VILI arises from the convergence of mechanical energy, regional stress, and structural vulnerability.

> **中文摘要：**
> 机械功率已成为量化呼吸机诱导肺损伤 (VILI) 风险的统一指标，它将潮气量、气道压力、呼吸频率和吸气气流等多个通气参数整合为传递到肺部的机械能的单一量度。然而，仅凭总机械功率无法完全预测损伤的可能性，因为 VILI 的发生不仅取决于传递的能量，还取决于这些能量如何与肺部的区域力学特性及其内在的应力脆弱性相互作用。至关重要的是，只有当外部测量的充气能量超过一个或多个局部肺泡应力阈值（称为危险弹性功率）时，才可能导致肺部损伤。在此背景下，我们提出了一种概念性方法，用于根据损伤的区域应力阈值来量化机械功率中这一具有破坏性的成分。一旦得到改进和验证，将这种方法整合到临床实践中，通过识别 VILI 是由机械能、区域应力及结构脆弱性共同作用而产生的，从而可能加强个体化的肺保护性通气策略。

### 第二部分 AI 大师评价

本文深入探讨了机械功率在预测呼吸机诱导肺损伤（VILI）中的局限性，并前瞻性地提出了“危险弹性功率”这一核心概念。文章指出，肺损伤并非仅由总能量决定，而是源于机械能与局部组织应力阈值之间的相互作用。这种从全局能量监测转向区域特异性损伤成分追踪的理论创新，为优化个体化肺保护性通气策略提供了关键的生物力学框架，具有极高的临床指导意义。

---

## 4. 悬吊式下肢康复设备在增强ICU获得性衰弱患者下肢功能中的疗效：一项自我对照随机临床试验

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41545879)
**期刊：** Critical care (London, England)
**PMID：** 41545879
**DOI：** 10.1186/s13054-026-05840-1

### 第一部分 原文与翻译

**英文原标题：** Efficacy of suspension-based lower-limb rehabilitation device in enhancing lower limb function among patients with ICU-acquired weakness: a self-controlled randomized clinical trial.

> **英文摘要：**
> BACKGROUND: Intensive Care Unit-acquired weakness (ICUAW) is a common and debilitating complication in critically ill patients, resulting in substantial functional impairment and reduced quality of life. Although early mobilization is widely recommended, the most effective rehabilitation strategy remains unclear. This study aimed to evaluate the short-term clinical efficacy of a suspension-based lower-limb rehabilitation device (SS) combined with conventional rehabilitation in prompt improvement of lower-limb function in patients with ICUAW after diagnosis. METHOD: A prospective, within-patient randomized controlled trial with a two-year study period. Sixty patients with ICUAW were enrolled, with one lower limb designated as the intervention side, receiving SS-assisted training plus standard physical therapy, and the opposite limb serving as the control, receiving standard physical therapy alone. Both limbs received 40 min of therapy daily, 5 days per week, for 2 consecutive weeks. Assessments were conducted at baseline (study enrolment), 1 week, and 2 weeks. The primary outcome was the change in lower-limb muscle thickness involving the rectus femoris, vastus intermedius, vastus medialis, vastus lateralis, and tibialis anterior, assessed by musculoskeletal ultrasound. Secondary outcomes included the Medical Research Council (MRC) score, active range of motion (AROM), and limb circumference. RESULTS: Mixed-effects model analysis of muscle thickness showed a significant interaction between group and time (p < 0.001) and a significant main effect of group (p = 0.001). Post-hoc analysis revealed that at two weeks, muscle thickness in the control limb was significantly lower than in the intervention limb (p < 0.01). In the control limb, muscle thickness was significantly reduced at both 1 week and 2 weeks compared with baseline (p < 0.01), with no significant difference between the two time points (p = 0.06). Notably, no significant within-group changes over time were observed in the intervention limb. Similarly, the control limb showed significantly lower MRC scores than the intervention limb at 1 week (p = 0.05) and 2 weeks (p = 0.003). AROM was also lower in the control limb at 1 week (p = 0.003) and 2 weeks (p < 0.001). No significant interaction or main effect was observed for lower-limb circumference (p = 0.18). CONCLUSION: Prompt intervention with SS-assisted rehabilitation combined with conventional therapy may help attenuate muscle atrophy, improve muscle strength, and enhance hip and knee AROM in patients with ICUAW, potentially offering a novel rehabilitation strategy for this population.

> **中文摘要：**
> 背景：ICU获得性衰弱（ICUAW）是危重症患者常见的致残性并发症，会导致严重的功能损伤和生活质量下降。尽管广泛推荐早期活动，但最有效的康复策略仍不明确。本研究旨在评估诊断后，悬吊式下肢康复设备（SS）结合常规康复对促进ICUAW患者下肢功能改善的短期临床疗效。方法：这是一项为期两年的前瞻性、患者自身随机对照试验。共纳入60名ICUAW患者，其中一侧下肢被指定为干预侧，接受SS辅助训练加标准物理治疗，对侧下肢作为对照组，仅接受标准物理治疗。双侧下肢每天接受40分钟治疗，每周5天，连续2周。评估分别在基线（入组时）、1周和2周进行。主要结局指标是通过肌肉骨骼超声评估的下肢肌肉厚度变化，包括股直肌、股中间肌、股内侧肌、股外侧肌和胫骨前肌。次要结局指标包括医学研究委员会（MRC）评分、主动关节活动度（AROM）和肢体周径。结果：肌肉厚度的混合效应模型分析显示，组别与时间之间存在显著交互作用（p < 0.001），且组别主效应显著（p = 0.001）。事后分析显示，两周时对照侧下肢的肌肉厚度显著低于干预侧（p < 0.01）。在对照侧，1周和2周时的肌肉厚度均较基线显著降低（p < 0.01），但这两个时间点之间无显著差异（p = 0.06）。值得注意的是，干预侧未观察到随时间变化的显著组内差异。同样，对照侧在1周（p = 0.05）和2周（p = 0.003）时的MRC评分显著低于干预侧。对照侧的AROM在1周（p = 0.003）和2周（p < 0.001）时也较低。下肢周径未观察到显著的交互作用或主效应（p = 0.18）。结论：对于ICUAW患者，尽早进行SS辅助康复结合常规治疗有助于减轻肌肉萎缩、提高肌力并改善髋膝关节AROM，可能为该人群提供一种新型康复策略。

### 第二部分 AI 大师评价

本研究采用创新的患者自身随机对照设计，严谨地评估了悬吊辅助训练在ICU获得性衰弱（ICUAW）康复中的应用价值。通过超声客观测量及肌力、关节活动度等多维度评估，研究证实该设备能显著延缓肌肉萎缩并提升运动功能，为重症早期康复提供了量化的循证依据。尽管研究为短期观察，但其发现对优化ICUAW临床康复路径、改善危重症患者长期预后具有重要的实践指导意义。

---

## 5. 1990-2023年204个国家苯丙胺、大麻、可卡因及阿片类药物使用的全球负担：一项全球疾病负担研究

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41545593)
**期刊：** Nature medicine
**PMID：** 41545593
**DOI：** 10.1038/s41591-025-04137-0

### 第一部分 原文与翻译

**英文原标题：** Global burden of amphetamine, cannabis, cocaine and opioid use in 204 countries, 1990-2023: a Global Burden of Disease Study.

> **英文摘要：**
> Drug use disorders (DUDs) are emerging global public health challenges. Here we investigated the global and regional estimates of the prevalence and burden of DUDs, including amphetamine, cannabis, cocaine and opioid use disorders, from 1990 to 2023 for 204 countries and territories by using the Global Burden of Disease Study 2023. Overall, trends in global age-standardized disability-adjusted life-years of DUDs increased from 169.3 (95% uncertainty interval (95% UI), 134.4-203.9) per 100,000 people in 1990 to 212.0 (95% UI, 179.2-245.6) in 2023. In 2023, both prevalence and burden of DUDs were higher in high-income countries, particularly in the USA. The most prevalent DUDs in 2023 were cannabis use disorder (age-standardized prevalence, 270.8 (95% UI, 201.7-350.0) per 100,000 people) and opioid use disorder (205.9 (95% UI, 178.7-235.0)). Particularly, opioid use disorder showed a nearly twofold increase in prevalence and burden between 1990 and 2023. In 2023, compared with countries where cannabis use was illegal, countries permitting both recreational and medical cannabis use had higher prevalence rates for all types of DUDs. Proactive and effective policies are essential to mitigate the increasing global burden of DUDs.

> **中文摘要：**
> 药物使用障碍（DUDs）是新出现的全球公共卫生挑战。本研究利用2023年全球疾病负担研究，调查了1990年至2023年间全球204个国家和地区苯丙胺、大麻、可卡因及阿片类药物使用障碍等DUDs的全球和区域流行率及负担估算。总体而言，全球DUDs的年龄标准化伤残调整寿命年（DALYs）趋势从1990年的每10万人169.3（95%不确定区间 (UI), 134.4-203.9）增加到2023年的212.0（95% UI, 179.2-245.6）。2023年，DUDs的流行率和负担在高收入国家（特别是美国）均更高。2023年最普遍的DUDs是大麻使用障碍（年龄标准化流行率为每10万人270.8（95% UI, 201.7-350.0））和阿片类药物使用障碍（205.9（95% UI, 178.7-235.0））。特别是，阿片类药物使用障碍的流行率和负担在1990年至2023年间显示出近两倍的增长。2023年，与大麻使用非法的国家相比，允许娱乐和医疗大麻用途的国家所有类型DUDs的流行率更高。采取主动且有效的政策对于减轻日益增长的全球DUDs负担至关重要。

### 第二部分 AI 大师评价

本研究基于2023年全球疾病负担研究的大规模数据，系统揭示了过去三十年间全球主要药物使用障碍负担的显著上升趋势。研究特别强调了高收入国家，尤其是美国在阿片类和大麻类药物障碍方面的严峻现状，并首次在宏观层面探讨了大麻合法化政策与多种药物障碍流行率之间的正相关性。该成果不仅量化了全球毒品问题的严重性，也为各国政府在权衡管制政策与公共卫生影响时提供了关键的决策依据。

---

## 6. 腺相关病毒基因治疗后肝脏中污染的质粒序列和受损的载体基因组

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41545588)
**期刊：** Nature medicine
**PMID：** 41545588
**DOI：** 10.1038/s41591-025-04073-z

### 第一部分 原文与翻译

**英文原标题：** Contaminating plasmid sequences and disrupted vector genomes in the liver following adeno-associated virus gene therapy.

> **英文摘要：**
> Adeno-associated viruses (AAVs) are common vectors in gene therapy but can frequently cause liver complications in patients. The mechanisms underlying AAV-related liver toxicity remain poorly understood, posing challenges for effective prevention and intervention. Here we conducted a case study of a child with spinal muscular atrophy type 1 experiencing substantial hepatitis after receiving onasemnogene abeparvovec, undertaking long- and short-read metagenomic sequencing of liver tissue. We identified manufacturing plasmid sequences with complex structures and recombination. Vector genomes had extensive disruption and concatemerization as well as numerous vector-human fusion junctions. We also identified human betaherpesvirus 6B in the liver. Further work and investigation of more patients is needed to establish whether the presence of manufacturing plasmid sequences or helper viruses contribute to the formation of these complex concatemeric DNA structures in the liver, and whether these are a factor in the development of liver toxicity after AAV gene therapy.

> **中文摘要：**
> 腺相关病毒 (AAV) 是基因治疗中常用的载体，但经常会导致患者出现肝脏并发症。AAV 相关肝毒性的潜在机制仍不明确，这给有效的预防和干预带来了挑战。在本研究中，我们对一名在接受 onasemnogene abeparvovec 治疗后出现严重肝炎的 1 型脊髓性肌萎缩症患儿进行了案例研究，并对肝组织进行了长读长和短读长宏基因组测序。我们鉴定出了具有复杂结构和重组的生产用质粒序列。载体基因组存在广泛的断裂和串联，以及大量的载体-人类融合接点。我们还在肝脏中鉴定出了人类 β 疱疹病毒 6B。需要进一步的工作和对更多患者的调查，以确定生产用质粒序列或辅助病毒的存在是否促进了肝脏中这些复杂串联 DNA 结构的形成，以及这些结构是否是 AAV 基因治疗后发生肝毒性的一个因素。

### 第二部分 AI 大师评价

本项案例研究通过对一名 AAV 基因治疗后出现严重肝炎患儿的肝组织进行深度宏基因组测序，首次在临床层面揭示了肝细胞内存在复杂的生产用残留质粒序列以及高度破碎并串联的载体基因组。研究不仅发现了大量的载体-宿主基因融合，还意外识别出辅助病毒的共感染，为 AAV 相关肝毒性的发生机制提供了全新的遗传学视角。尽管该发现源于单病例研究，但它有力地提示了基因治疗产品纯度监测及病毒序列整合风险评估在保障患者安全中的核心价值。

---

## 7. 助力肺泡巨噬细胞在病毒性肺炎期间存活以持续抗争

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41542776)
**期刊：** The Journal of clinical investigation
**PMID：** 41542776
**DOI：** 10.1172/JCI201457

### 第一部分 原文与翻译

**英文原标题：** Helping alveolar macrophages live to fight another day during viral pneumonia.

> **英文摘要：**
> Alveolar macrophages (AMs) help defend the lungs against infection, but during pneumonia many alveolar macrophages die. In this issue of the JCI, Malainou et al. explored the mechanism underpinning AM death during viral pneumonia and its effect on the outcomes of bacterial superinfection, a secondary infection that occurs before the first infection is cleared. In mouse models of influenza A infection, recruited neutrophils secreted TNF superfamily member 14 (TNFSF14), and AMs increased expression of the TNFSF14 receptors TNFSFR14 and type I transmembrane lymphotoxin β receptor (LTβR). TNFSF14 signaling via the LTβR was sufficient to cause AM apoptosis. TNFSF14 deficiency or blockade preserved AMs during influenza infection and diminished bacterial burdens and mouse mortality during pneumococcal superinfection. The adoptive transfer of AMs decreased the severity of pneumococcal superinfections, if those AMs lacked the LTβR. Thus, preserving AMs by interrupting TNFRSF14-LTβR interactions can make virus-infected lungs less susceptible to severe bacterial superinfection.

> **中文摘要：**
> 肺泡巨噬细胞（AMs）有助于保护肺部免受感染，但在肺炎期间，许多肺泡巨噬细胞会死亡。在本期 JCI 中，Malainou 等人探讨了病毒性肺炎期间 AM 死亡的潜在机制，及其对细菌继发感染（在首次感染清除前发生的二次感染）结果的影响。在甲型流感感染的小鼠模型中，招募的中性粒细胞分泌肿瘤坏死因子超家族成员 14 (TNFSF14)，而 AM 增加了 TNFSF14 受体 TNFSFR14 和 I 型跨膜淋巴毒素 β 受体 (LTβR) 的表达。通过 LTβR 进行的 TNFSF14 信号传导足以导致 AM 凋亡。在流感感染期间，TNFSF14 的缺失或阻断保留了 AM，并减少了肺炎球菌继发感染期间的细菌负荷和小鼠死亡率。如果过继转移的 AM 缺乏 LTβR，则能降低肺炎球菌继发感染的严重程度。因此，通过阻断 TNFRSF14-LTβR 相互作用来保护 AM，可以降低病毒感染的肺部对严重细菌继发感染的易感性。

### 第二部分 AI 大师评价

本文揭示了病毒性肺炎导致肺泡巨噬细胞（AM）耗损的关键分子机制，重点阐述了中性粒细胞分泌的TNFSF14通过LTβR受体诱导AM凋亡的过程。研究通过流感病毒感染的小鼠模型证明，阻断该信号通路或过继转移缺乏LTβR的AM可显著维持肺部免疫防御功能，降低继发性肺炎球菌感染的细菌负荷及病死率。该研究为临床防治病毒感染后的致死性继发细菌感染提供了新的免疫学靶点和治疗策略。

---

## 8. 一种人类大脑发育所需的转座酶衍生基因

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41533792)
**期刊：** Science advances
**PMID：** 41533792
**DOI：** 10.1126/sciadv.adv7530

### 第一部分 原文与翻译

**英文原标题：** A transposase-derived gene required for human brain development.

> **英文摘要：**
> Vertebrate brain development is associated with prominent neuronal cell death and DNA breaks, but their causes and functions are not well understood. DNA transposable elements could contribute to somatic genome rearrangements; however, their contributions to brain development are largely unknown. PiggyBac transposable element derived 5 (PGBD5) is an evolutionarily conserved vertebrate DNA transposase-derived gene with DNA remodeling activities in human cells. Here, we show that PGBD5 contributes to normal brain development in mice and humans, and its deficiency causes disorder of intellectual disability, movement disorders, and epilepsy. In mice, Pgbd5 is required for the developmental induction of postmitotic DNA breaks and recurrent somatic brain genome rearrangements. In the cerebral cortex, loss of Pgbd5 leads to aberrant neuronal gene expression, including of specific types of glutamatergic neurons, which partly explains the features of PGBD5 deficiency in humans. Thus, PGBD5 is a transposase-derived gene required for brain development in mammals.

> **中文摘要：**
> 脊椎动物大脑发育与显著的神经元细胞死亡和 DNA 断裂相关，但其原因和功能尚不十分清楚。DNA 转座元件可能有助于体细胞基因组重组；然而，它们对大脑发育的贡献在很大程度上是未知的。PiggyBac 转座元件衍生 5 (PGBD5) 是一种进化上保守的脊椎动物 DNA 转座酶衍生基因，在人类细胞中具有 DNA 重塑活性。在这里，我们证明了 PGBD5 有助于小鼠和人类的正常大脑发育，其缺失会导致智力障碍、运动障碍和癫痫。在小鼠中，Pgbd5 是诱导有丝分裂后 DNA 断裂和反复发生的体细胞大脑基因组重组所必需的。在大脑皮层中，Pgbd5 的缺失会导致异常的神经元基因表达，包括特定类型的谷氨酸能神经元，这部分解释了人类 PGBD5 缺乏症的特征。因此，PGBD5 是一种哺乳动物大脑发育所需的转座酶衍生基因。

### 第二部分 AI 大师评价

本研究揭示了进化保守的转座酶衍生基因 PGBD5 在哺乳动物大脑发育中的核心作用。通过整合小鼠模型与人类临床病例，作者证实了 PGBD5 介导的体细胞基因组重组是正常神经发育的关键环节，其功能缺陷会导致智力障碍和癫痫等严重神经系统疾患。该发现不仅确立了 PGBD5 的致病地位，还从分子水平探讨了非经典基因组重塑如何驱动大脑复杂性的构建，具有重要的生物学意义和临床诊断价值。

---

## 9. 翻译标题未提供

**期刊：** 期刊信息缺失
**PMID：** PMID未提供

### 第一部分 原文与翻译

**英文原标题：** 原文标题未提供

> **英文摘要：**
> 原文摘要未提供

> **中文摘要：**
> 翻译摘要未提供

### 第二部分 AI 大师评价

AI评价未提供

---

## 10. 机械应变在基于类器官的肺炎芯片模型中加剧铜绿假单胞菌感染

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41252215)
**期刊：** The Journal of clinical investigation
**PMID：** 41252215
**DOI：** 10.1172/JCI192454

### 第一部分 原文与翻译

**英文原标题：** Mechanical strain exacerbates Pseudomonas infection in an organoid-based pneumonia-on-a-chip model.

> **英文摘要：**
> Using an advanced human lung-on-a-chip model, this study shows that increased mechanical strain can make the lungs more vulnerable to harmful bacteria such as Pseudomonas aeruginosa.

> **中文摘要：**
> 本研究利用先进的人体肺芯片模型，表明增加的机械应变会使肺部更容易受到铜绿假单胞菌等有害细菌的侵害。

### 第二部分 AI 大师评价

本研究通过先进的人体肺芯片模型，揭示了物理机械力与生物感染之间的关键相互作用。研究核心发现机械应变的增加会显著提升肺部对铜绿假单胞菌的易感性，为理解机械通气相关性肺炎的病理机制提供了新视角。该模型成功整合了类器官技术与器官芯片技术，具有极高的科研创新性，为临床干预呼吸力学诱导的肺部感染提供了重要的体外实验平台。

---

## 11. TNF超家族成员14驱动流感后肺泡巨噬细胞耗竭，从而导致继发性肺炎链球菌肺炎

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41252214)
**期刊：** The Journal of clinical investigation
**PMID：** 41252214
**DOI：** 10.1172/JCI185390

### 第一部分 原文与翻译

**英文原标题：** TNF superfamily member 14 drives post-influenza depletion of alveolar macrophages, enabling secondary pneumococcal pneumonia.

> **英文摘要：**
> Secondary bacterial infection, often caused by Streptococcus pneumoniae, is one of the most frequent and severe complications of influenza A virus-induced (IAV-induced) pneumonia. Phenotyping of the pulmonary immune cell landscape after IAV infection revealed a substantial depletion of the tissue-resident alveolar macrophage (TR-AM) population at day 7, which was associated with increased susceptibility to S. pneumoniae outgrowth. To elucidate the molecular mechanisms underlying TR-AM depletion, and to define putative targets for treatment, we combined single-cell transcriptomics and cell-specific PCR profiling in an unbiased manner, using in vivo models of IAV infection and IAV and S. pneumoniae coinfection. The TNF superfamily 14 (TNFSF14) ligand/receptor axis was revealed as the driving force behind post-influenza TR-AM death during the early infection phase, enabling the transition to pneumococcal pneumonia, whereas intrapulmonary transfer of genetically modified TR-AMs and antibody-mediated neutralization of specific pathway components alleviated disease severity. With mainly neutrophilic expression and high abundance in the bronchoalveolar fluid of patients with severe virus-induced acute respiratory distress syndrome, TNFSF14 emerged as a key determinant of virus-driven lung injury. Targeting the TNFSF14-mediated intercellular communication network in the virus-infected lung can, therefore, improve host defense, minimizing the risk of subsequent bacterial pneumonia and ameliorating the disease outcome.

> **中文摘要：**
> 继发性细菌感染（通常由肺炎链球菌引起）是甲型流感病毒（IAV）诱导的肺炎中最频繁且最严重的并发症之一。对IAV感染后肺部免疫细胞图谱的表型分析显示，在第7天组织驻留肺泡巨噬细胞（TR-AM）群体显著耗竭，这与肺炎链球菌过度生长的易感性增加有关。为了阐明TR-AM耗竭的分子机制并确定潜在的治疗靶点，我们采用公正的方法，利用IAV感染以及IAV和肺炎链球菌共感染的体内模型，结合了单细胞转录组学和细胞特异性PCR谱分析。研究揭示，TNF超家族14（TNFSF14）配体/受体轴是早期感染阶段流感后TR-AM死亡的驱动力，促进了向肺炎链球菌肺炎的转变；而肺内移植基因修饰的TR-AMs以及抗体介导的特定通路组分中和则减轻了疾病严重程度。TNFSF14主要在嗜中性粒细胞中表达，且在病毒诱导的严重急性呼吸窘迫综合征患者的支气管肺泡灌洗液中含量丰富，成为病毒驱动肺损伤的关键决定因素。因此，靶向病毒感染肺部中TNFSF14介导的细胞间通讯网络可以增强宿主防御，降低后续细菌性肺炎的风险，并改善疾病预后。

### 第二部分 AI 大师评价

本研究深入揭示了流感继发细菌性肺炎的关键免疫病理机制，确立了TNFSF14在驱动肺泡巨噬细胞（TR-AM）耗竭中的核心地位。通过整合单细胞转录组学与体内共感染模型，作者证实了阻断TNFSF14轴能有效维持肺部免疫稳态并降低继发感染易感性。该研究不仅发现了重症病毒性肺炎的新生物标志物，还为防治流感相关继发性肺炎提供了极具前景的免疫治疗靶点。

---

## 12. 载达托霉素纳米载体通过脂质介导的相互作用与靶向作用促进协同杀灭耐甲氧西林金黄色葡萄球菌

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41189495)
**期刊：** The Journal of infectious diseases
**PMID：** 41189495
**DOI：** 10.1093/infdis/jiaf492

### 第一部分 原文与翻译

**英文原标题：** Daptomycin-Loaded Nanocarriers Facilitate Synergistic Killing of Methicillin-Resistant Staphylococcus aureus via Lipid-Mediated Interactions and Targeting.

> **英文摘要：**
> Preservation and augmentation of existing antimicrobials is crucial in combating antimicrobial resistance. Gram-positive bacteria, exemplified by Staphylococcus aureus, are among the most common human bacterial pathogens, with methicillin-resistant S. aureus (MRSA) now established globally. Daptomycin is a last-line anti-staphylococcal antimicrobial that uniquely targets the bacterial membrane with bactericidal effects. Here, we developed lipid-based nanoparticles, namely cubosomes, to encapsulate daptomycin for targeted delivery via lipid-mediated interactions. Daptomycin-loaded cubosomes synergistically killed 14 clinical MRSA isolates in vitro compared with daptomycin or cubosomes alone. This synergy between daptomycin and cubosome was mediated by cubosomes docking on the S. aureus cell surface, releasing daptomycin for membrane extraction and penetration, followed by lipid cubosome infusion into S. aureus membranes. Using a murine septicemia model, daptomycin-loaded cubosomes significantly reduced the organ bacterial burden of MRSA. Together, these data showed that multifunctional lipid nanocarriers can potentiate the bactericidal activity of daptomycin using a membrane-targeted trojan-horse-like mechanism.

> **中文摘要：**
> 保护和增强现有抗菌药物对于对抗抗菌素耐药性至关重要。以金黄色葡萄球菌为代表的革兰氏阳性菌是最常见的人类致病菌之一，耐甲氧西林金黄色葡萄球菌（MRSA）目前已在全球范围内流行。达托霉素是一种用于治疗葡萄球菌感染的最后一道防线药物，其通过独特地靶向细菌细胞膜产生杀菌作用。在此，我们开发了基于脂质的纳米颗粒，即立方体纳米粒子（cubosomes），用于封装达托霉素，通过脂质介导的相互作用实现靶向递送。与单独使用达托霉素或立方体纳米粒子相比，载有达托霉素的立方体纳米粒子在体外协同杀灭了14株MRSA临床分离株。达托霉素与立方体纳米粒子之间的这种协同作用是由立方体纳米粒子对接在金黄色葡萄球菌细胞表面，释放达托霉素进行膜提取和穿透，随后脂质立方体纳米粒子注入金黄色葡萄球菌膜介导的。在小鼠败血症模型中，载有达托霉素的立方体纳米粒子显著降低了MRSA引起的器官细菌负荷。总之，这些数据表明，多功能脂质纳米载体可以利用膜靶向的“木马”式机制增强达托霉素的杀菌活性。

### 第二部分 AI 大师评价

该研究针对耐药金黄色葡萄球菌（MRSA）的临床挑战，创新性地开发了载达托霉素的脂质立方体纳米递送系统。通过体外实验和小鼠败血症模型，研究证明了该纳米载体能通过独特的“木马”式膜靶向机制，显著增强达托霉素的杀菌效力。这种脂质介导的协同作用不仅提高了药物渗透性，还降低了组织细菌负荷，为开发应对抗生素耐药性的新型纳米药物平台提供了强有力的证据。

---

## 13. 异基因造血细胞移植后的呼吸道病毒感染与肺损伤

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41027579)
**期刊：** The Journal of infectious diseases
**PMID：** 41027579
**DOI：** 10.1093/infdis/jiaf503

### 第一部分 原文与翻译

**英文原标题：** Respiratory Virus Infections and Pulmonary Impairment After Allogeneic Hematopoietic Cell Transplantation.

> **英文摘要：**
> BACKGROUND: Respiratory virus infections (RVIs) are common after hematopoietic cell transplantation (HCT), but their effect on pulmonary outcomes, including bronchiolitis obliterans syndrome (BOS), and mortality is poorly defined. METHODS: Prospective cohort study of 471 allogeneic HCT recipients transplanted in the pre-COVID-19 pandemic era in an academic cancer center. Participants were prospectively followed for 1 year with serial handheld spirometry, symptom questionnaires, and multiplex 11-virus PCR. Pulmonary function testing occurred at recommended intervals. Cox proportional hazard and generalized estimating equation models were used to estimate associations between RVI and weekly spirometry with late airflow obstruction (AFO), BOS, and overall mortality. RESULTS: The 1-year cumulative incidence of at least one RVI was 62%; lower respiratory tract disease (LRTD) occurred in 7.6% of patients. Late AFO developed in 15.6% of patients and BOS in 3.9% of patients. Any symptomatic viral upper respiratory tract infections (URTI) were associated with AFO (adjusted HR [aHR] 1.87, 95% CI 1.11-3.16) and BOS (aHR 2.65, 95% CI 1.02-6.91). Individually, PIV-3 URTIs were associated with AFO (aHR 2.83, 95% CI 1.01-7.97) and RSV URTIs were associated with BOS (aHR 6.32, 95% CI 2.04-19.6). Short-term airflow decline was associated with AFO. Any LRTD (aHR 3.49, 95% CI 2.18-5.57), as well as symptomatic influenza URTI (aHR 2.68, 95% CI 1.52-4.72), were associated with mortality. CONCLUSIONS: RVI after HCT, particularly those caused by RSV, PIV-3, and influenza, increase the risk of pulmonary impairment and mortality. These infections should be targeted for specific anti-viral approaches and intensified monitoring for late onset pulmonary disease.

> **中文摘要：**
> 背景：呼吸道病毒感染（RVIs）在造血细胞移植（HCT）后十分常见，但其对肺部预后（包括闭塞性细支气管炎综合征，BOS）以及死亡率的影响尚不明确。方法：本项前瞻性队列研究纳入了在COVID-19大流行前时代，于一家学术癌症中心接受移植的471名异基因造血细胞移植受者。受试者接受了为期1年的前瞻性随访，包括定期手持肺功能仪监测、症状调查问卷和11种病毒的多重PCR检测。肺功能测试按推荐间隔进行。使用Cox比例风险模型和广义估计方程模型评估呼吸道病毒感染、每周肺功能测定值与晚期气流阻塞（AFO）、BOS及全因死亡率之间的关联。结果：1年内至少发生一次呼吸道病毒感染的累积发病率为62%；下呼吸道疾病（LRTD）见于7.6%的患者。15.6%的患者发生了晚期气流阻塞，3.9%的患者发生了BOS。任何有症状的病毒性上呼吸道感染（URTI）均与气流阻塞（调整后风险比[aHR] 1.87, 95% CI 1.11-3.16）和BOS（aHR 2.65, 95% CI 1.02-6.91）相关。具体而言，副流感病毒3型（PIV-3）上呼吸道感染与气流阻塞相关（aHR 2.83, 95% CI 1.01-7.97），而呼吸道合胞病毒（RSV）上呼吸道感染与BOS相关（aHR 6.32, 95% CI 2.04-19.6）。短期气流下降与晚期气流阻塞相关。任何下呼吸道疾病（aHR 3.49, 95% CI 2.18-5.57）以及有症状的流感上呼吸道感染（aHR 2.68, 95% CI 1.52-4.72）均与死亡率相关。结论：造血细胞移植后的呼吸道病毒感染，特别是由于RSV、PIV-3和流感病毒引起的感染，会增加肺损伤和死亡的风险。应针对这些感染实施特定的抗病毒治疗策略，并加强对迟发型肺部疾病的监测。

### 第二部分 AI 大师评价

该前瞻性队列研究系统地阐明了异基因造血细胞移植（HCT）后，呼吸道病毒感染（RVI）对远期肺功能损伤及生存率的负面影响。研究通过密集的手持肺功能监测和多重PCR筛查，揭示了特定病毒如RSV和PIV-3在诱发BOS和气流阻塞中的关键作用，打破了“上呼吸道感染仅为自限性疾病”的传统认知。其创新点在于将病毒特异性与肺部生理指标的动态变化相结合，为临床早期风险识别提供了数据支持。结论强调了对此类患者进行靶向抗病毒干预及强化肺部监测的迫切性。

---

## 14. 生理相关条件下阿奇霉素对抗产超广谱β-内酰胺酶（ESBL）大肠杆菌活性的研究

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/40974066)
**期刊：** The Journal of infectious diseases
**PMID：** 40974066
**DOI：** 10.1093/infdis/jiaf480

### 第一部分 原文与翻译

**英文原标题：** Investigating Azithromycin Activity Against ESBL-Producing Escherichia coli Under Physiologically Relevant Conditions.

> **英文摘要：**
> Extended-spectrum beta-lactamase (ESBL)-producing Escherichia coli are a major antimicrobial resistance threat. Although not standard therapy, azithromycin (AZM) displayed potent activity against ESBL E. coli in vitro, ex vivo, and in vivo. AZM demonstrated multi-fold reductions in MIC, bactericidal activity in supplemented mammalian tissue culture media, and enhanced dose-dependent activity with sodium bicarbonate (NaHCO3). AZM also augmented complement-mediated killing in human serum and improved survival by 50% in a murine bloodstream infection model. These findings underscore the need to revisit antibiotic susceptibility testing-incorporating host defense factors and NaHCO3-and suggest AZM merits further clinical evaluation for ESBL E. coli infections.

> **中文摘要：**
> 产超广谱β-内酰胺酶（ESBL）的大肠杆菌是全球主要的抗菌药物耐药威胁。尽管阿奇霉素（AZM）并非标准疗法，但在体外、离体和体内实验中，它均表现出对抗产 ESBL 大肠杆菌的强效活性。研究表明，在补充了哺乳动物组织培养基的条件下，AZM 的最小抑菌浓度（MIC）呈现数倍降低，并表现出杀菌活性，且在碳酸氢钠（NaHCO3）存在时其剂量依赖性活性进一步增强。此外，AZM 还增强了人血清中补体介导的杀伤作用，并在小鼠血流感染模型中将生存率提高了 50%。这些发现强调了重新审视抗生素药敏试验的必要性（即应纳入宿主防御因子和 NaHCO3），并表明 AZM 值得在治疗产 ESBL 大肠杆菌感染方面进行进一步的临床评估。

### 第二部分 AI 大师评价

本研究通过模拟生理微环境，揭示了阿奇霉素在传统药敏试验中被掩盖的抗产ESBL大肠杆菌的高效能，具有重要的临床指导意义。研究综合运用了体外培养、血清补体实验及动物模型，系统性地证实了碳酸氢钠及宿主免疫因子对药物活性的显著增强作用。其创新之处在于挑战了现行的药敏评估标准，提出应结合生理相关因子以更准确地评价抗生素活性，为多重耐药菌的治疗提供了老药新用的潜力和新视角。

---

## 15. 2025年美国传染病学会关于2019冠状病毒病（COVID-19）治疗与管理的临床实践指南更新：阿巴西普

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/40923137)
**期刊：** Clinical infectious diseases : an official publication of the Infectious Diseases Society of America
**PMID：** 40923137
**DOI：** 10.1093/cid/ciaf354

### 第一部分 原文与翻译

**英文原标题：** 2025 Clinical Practice Guideline Update by the Infectious Diseases Society of America on the Treatment and Management of COVID-19: Abatacept.

> **英文摘要：**
> This article provides a focused update to the clinical practice guideline on the treatment and management of patients with coronavirus disease 2019 (COVID-19), developed by the Infectious Diseases Society of America. The guideline panel presents a recommendation on the use of abatacept in hospitalized adults with severe or critical COVID-19. The recommendation is based on evidence derived from a systematic literature review and adheres to a standardized methodology for rating the certainty of evidence and strength of recommendation according to the GRADE (Grading of Recommendations, Assessment, Development, and Evaluation) approach.

> **中文摘要：**
> 本文提供了由美国传染病学会（IDSA）制定的2019冠状病毒病（COVID-19）患者治疗与管理临床实践指南的专项更新。指南专家组针对阿巴西普在住院重症或危重症COVID-19成年患者中的应用提出了建议。该建议基于对系统性文献回顾所获得的证据，并遵循标准化的方法，根据GRADE（推荐分级的评估、制定与评价）方法对证据的确定性和推荐强度进行评级。

### 第二部分 AI 大师评价

该指南更新反映了针对重症COVID-19治疗方案的最新循证医学动态，重点关注免疫调节剂阿巴西普的应用。通过严谨的GRADE方法学评估，IDSA为临床医生提供了具有高证据等级的决策支持，确保了临床路径的科学性。其核心价值在于针对特定药物进行快速专项更新，有效缩短了从高质量证据产生到临床实践转化之间的时间差。

---

## 16. 2016年与2023年澳大利亚东北部献血者军团菌抗体血清流行率研究

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/40905692)
**期刊：** The Journal of infectious diseases
**PMID：** 40905692
**DOI：** 10.1093/infdis/jiaf407

### 第一部分 原文与翻译

**英文原标题：** Seroprevalence of Antibodies Against Legionella Species in Northeastern Australian Blood Donors, 2016 and 2023.

> **英文摘要：**
> BACKGROUND: In 2021-2022, Queensland, Australia observed an increase in Legionnaire's disease cases, predominantly due to Legionella longbeachae. This study assessed seroprevalence at time points 2016 and 2023, representing before and after the higher incidence and explored if demographic, environmental and geographical factors associated with legionellosis seroprevalence.
> 
> METHODS: A total of 1001 human plasma samples (496 from 2016/505 from 2023) were analysed for the presence of Legionella antibodies (IgG) using indirect immunofluorescence assays. Primary screens detected IgG to L. pneumophila serogroups (SG) 1-6, SG 7-14, or "other" Legionella spp. Samples positive for "other" underwent secondary screening for L. longbeachae SG 1 and 2. A chi-square test assessed associations between seroprevalence and demographics, while a generalized linear model evaluated rainfall, temperature, and land cover associations.
> 
> RESULTS: While total Legionella seroprevalence remained stable (32.46% vs 32.28%) between 2016 and 2023, we observed a decrease in L. pneumophila (SG 1-6: 19%-13% [P = .0182] and SG 7-14: 24%-18% [P = .0257]) and an increase in L. longbeachae (1%-3% [P = .0355]) seropositivity. L. pneumophila seroprevalence positively associated with higher rainfall and land cover, with croplands and urban areas showing increased prevalence.
> 
> CONCLUSIONS: Between 2016 and 2023, total Legionella seroprevalence remained unchanged. However, rainfall and specific land cover types were positively associated with seropositivity for certain Legionella spp. This study highlights the importance of assessing Legionella exposure risks in high-risk areas, particularly for vulnerable individuals such as the elderly, immunosuppressed, or those with co-morbidities.

> **中文摘要：**
> 背景：2021-2022年间，澳大利亚昆士兰州的军团病（Legionnaire's disease）病例有所增加，主要由长滩军团菌（Legionella longbeachae）引起。本研究评估了2016年和2023年这两个时间点的血清流行率（分别代表高发病率期之前和之后），并探讨了人口统计学、环境和地理因素是否与军团菌病的血清流行率相关。
> 
> 方法：利用间接免疫荧光法对共计1001份人类血清样本（2016年496份，2023年505份）进行了军团菌抗体（IgG）检测。初筛检测了针对嗜肺军团菌（L. pneumophila）血清型（SG）1-6、SG 7-14或“其他”军团菌属的IgG。对“其他”类阳性的样本进行了长滩军团菌SG 1和2的二次筛查。使用卡方检验评估血清流行率与人口统计学之间的关联，并利用广义线性模型评估降雨量、温度和土地覆盖的关联性。
> 
> 结果：虽然2016年至2023年间的总军团菌血清流行率保持稳定（32.46% vs 32.28%），但我们观察到嗜肺军团菌的血清阳性率有所下降（SG 1-6：19%-13% [P = .0182]；SG 7-14：24%-18% [P = .0257]），而长滩军团菌的血清阳性率有所上升（1%-3% [P = .0355]）。嗜肺军团菌的血清流行率与较高的降雨量和土地覆盖呈正相关，其中农田和城市地区的流行率较高。
> 
> 结论：2016年至2023年间，军团菌的总血清流行率未发生改变。然而，降雨量和特定的土地覆盖类型与某些军团菌属的血清阳性率呈正相关。本研究强调了在评估高风险地区军团菌暴露风险的重要性，特别是针对老年人、免疫功能受损者或患有合并症等易感人群。

### 第二部分 AI 大师评价

本研究通过对比分析昆士兰州军团病暴发前后的献血者血清样本，揭示了当地军团菌暴露谱系的动态漂移，尤其是长滩军团菌血清阳性率的显著上升。研究创新性地结合了气象与地理信息数据，确证了降雨量、农田及城镇土地利用对军团菌传播风险的潜在促进作用。尽管献血者群体存在“健康参试者”偏倚，但该研究为针对脆弱人群的区域性环境风险评估和精准预防提供了重要的流行病学依据。

---

## 17. 坦桑尼亚北部人血流、人与动物粪便及环境中分离的大肠埃希氏菌种群结构研究

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/40825555)
**期刊：** The Journal of infectious diseases
**PMID：** 40825555
**DOI：** 10.1093/infdis/jiaf437

### 第一部分 原文与翻译

**英文原标题：** Population Structure of Escherichia coli Isolated From the Human Bloodstream, Human and Animal Feces, and the Environment in Northern Tanzania.

> **英文摘要：**
> BACKGROUND: Extraintestinal pathogenic Escherichia coli (ExPEC) are a leading cause of human bloodstream infections (BSIs) in sub-Saharan Africa, yet few studies have characterized African strains implicated in BSI or explored their potential reservoirs.
> 
> METHODS: We enrolled febrile patients at 2 hospitals in Moshi, Tanzania, 2007-2019, and performed blood cultures. Whole-genome sequencing was conducted on E. coli originating from the bloodstream to characterize sequence types (STs), serotypes, and theoretical coverage of a 9-valent ExPEC polysaccharide conjugate vaccine (ExPEC9V). Separately, we evaluated 601 E. coli whole-genome sequences from humans, animals, and environmental sources in nearby communities. We assessed genetic relatedness between bloodstream and community isolates based on single-nucleotide polymorphisms and allele differences.
> 
> FINDINGS: Of 3046 participants receiving blood culture, 48 (0.2%) had BSI yielding 48 E. coli isolates. The median (range) age of participants with E. coli BSI was 40.7 (0.3-89.0) years, and 32 (68.1%) were female. We identified 16 STs including ST131 (n = 16, 33.3%), ST73 (n = 10, 20.8%), and ST69 (n = 6, 12.5%) and 19 O groups including O25 (n = 13, 27.1%), O6 (n = 10, 20.3%), O17 (n = 4, 8.3%), and O18 (n = 4, 8.3%). Theoretical coverage for an ExPEC9V was 72.9%. None of the bloodstream and community E. coli pairs were closely related.
> 
> CONCLUSIONS: We found a high diversity of STs among E. coli human bloodstream isolates in Tanzania. Despite this diversity, we observed that an EXPEC9V in development would provide good coverage. Reservoir-attribution studies at finer spatial and temporal scales may better identify transmission networks and reservoirs of ExPECs.

> **中文摘要：**
> 背景：肠外致病性大肠埃希氏菌（ExPEC）是撒哈拉以南非洲地区人类血流感染（BSIs）的主要原因，但很少有研究对涉及血流感染的非洲菌株进行表征或探索其潜在的宿主。方法：我们于2007年至2019年在坦桑尼亚莫希的两家医院招募了发热患者，并进行了血培养。对源自血流的大肠埃希氏菌进行了全基因组测序，以表征其序列类型（STs）、血清型以及一种9价ExPEC多糖结合疫苗（ExPEC9V）的理论覆盖率。另外，我们评估了来自附近社区的人类、动物和环境源的601个大肠埃希氏菌全基因组序列。我们根据单核苷酸多态性和等位基因差异评估了血流分离株与社区分离株之间的遗传亲缘关系。结果：在接受血培养的3046名参与者中，48名（0.2%）患有血流感染并分离出48株大肠埃希氏菌。大肠埃希氏菌血流感染参与者的中位年龄（范围）为40.7（0.3-89.0）岁，其中32名（68.1%）为女性。我们鉴定了16种序列类型（STs），包括ST131（n = 16, 33.3%）、ST73（n = 10, 20.8%）和ST69（n = 6, 12.5%），以及19个O抗原组，包括O25（n = 13, 27.1%）、O6（n = 10, 20.3%）、O17（n = 4, 8.3%）和O18（n = 4, 8.3%）。ExPEC9V的理论覆盖率为72.9%。血流与社区大肠埃希氏菌配对中没有一对表现出密切的亲缘关系。结论：我们发现坦桑尼亚人类血流大肠埃希氏菌分离株中存在高度的序列类型多样性。尽管存在这种多样性，我们观察到正在开发中的ExPEC9V将提供良好的覆盖。在更精细的空间和时间尺度上进行宿主归属研究可能会更好地识别ExPECs的传播网络和宿主。

### 第二部分 AI 大师评价

本研究利用全基因组测序技术，深入分析了坦桑尼亚引起血流感染的大肠埃希氏菌（ExPEC）的种群结构与遗传多样性。研究重点揭示了ST131等国际流行克隆株在当地的主导地位，并证实了研发中的9价疫苗具有高达72.9%的理论覆盖率，具有重要的临床预防价值。虽然研究未在当地环境或动物样本中发现与血流感染株直接相关的遗传证据，但为非洲地区肠外致病性大肠杆菌的基因组监测和疫苗策略提供了坚实的科学依据。

---

## 18. 低内在杀菌活性及其阳性结果对 3 期肺炎球菌疫苗成人研究无影响

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/40796175)
**期刊：** The Journal of infectious diseases
**PMID：** 40796175
**DOI：** 10.1093/infdis/jiaf427

### 第一部分 原文与翻译

**英文原标题：** Low Intrinsic Killing Activity and no Impact of Its Positivity on Phase 3 Pneumococcal Vaccine Adult Studies.

> **英文摘要：**
> BACKGROUND: The opsonophagocytic assay (OPA) is the gold standard for measuring functional antibody responses to bacterial vaccines. However, antibody-independent bactericidal activities, such as those by antibiotics, could contribute to the killing and thus inflate the measured antibody titer. Because of this, an intrinsic killing (IK) assay is currently required to screen and exclude samples with antibody-independent bactericidal activities. METHODS: Here, we utilized multiple phase 3 studies of V116 (Capvaxive), as well as in vitro antibiotic spiked samples with known OPA titers, to gain in-depth insights regarding the impact and necessity of the IK screening testing. RESULTS: Our results show that even at the highest clinically relevant blood concentration, an antibiotic such as amoxicillin only contributes to a titer of about 50 in the antibody-depleted serum sample. Consistent with this, IK positivity in V116 phase 3 studies only showed higher geometric mean titers (GMTs) in the pre-vaccinated, baseline population when the GMTs are lower than 320. After vaccination, no significant differences in OPA titers were observed between IK-positive and IK-negative samples. This, combined with the low rate of IK positivity in healthy adults of V116 clinical studies (≤2% in each study), demonstrated that including IK-positive samples did not alter the relevant clinical assessments of opsonophagocytic activity. CONCLUSIONS: Thus, eliminating the IK assay as a requirement for OPA testing could be considered in healthy adult populations where antibiotic use is well-regulated.

> **中文摘要：**
> 背景：调理吞噬试验 (OPA) 是衡量细菌疫苗功能性抗体反应的金标准。然而，与抗体无关的杀菌活性（如抗生素产生的活性）可能会促成杀菌效果，从而虚增测得的抗体滴度。因此，目前需要进行内在杀菌 (IK) 试验来筛选并排除具有抗体无关杀菌活性的样本。方法：本研究利用了 V116 (Capvaxive) 的多项 3 期研究，以及具有已知 OPA 滴度的体外添加抗生素的样本，旨在深入了解 IK 筛选检测的影响和必要性。结果：我们的结果显示，即使在临床相关的最高血药浓度下，阿莫西林等抗生素在去除抗体的血清样本中也仅产生约 50 的滴度。与此一致的是，在 V116 3 期研究中，只有当几何平均滴度 (GMT) 低于 320 时，IK 阳性才在接种前的基线人群中显示出较高的 GMT。接种疫苗后，IK 阳性和 IK 阴性样本之间的 OPA 滴度未观察到显著差异。结合 V116 临床研究中健康成人 IK 阳性率较低（每项研究均 ≤2%）的情况，这表明纳入 IK 阳性样本并未改变调理吞噬活性的相关临床评估。结论：因此，在抗生素使用受到严格监管的健康成人人群中，可以考虑取消将 IK 试验作为 OPA 检测的必要要求。

### 第二部分 AI 大师评价

该研究系统评估了内在杀菌（IK）活性对肺炎球菌疫苗（V116）3期临床试验中调理吞噬试验（OPA）结果的影响。研究发现，即使在高浓度抗生素存在下，其对滴度的贡献也极其有限，且 IK 阳性在健康成人接种后样本中无显著临床影响。研究的创新性在于通过大规模 3 期临床数据证明了 IK 筛选在健康成人受试者中的低价值，为简化疫苗免疫原性评估流程、提高检测效率提供了科学依据。

---

## 19. ST3390 的出现：一种来自 CC5 谱系的新型无色素 MRSA 克隆

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/40795157)
**期刊：** The Journal of infectious diseases
**PMID：** 40795157
**DOI：** 10.1093/infdis/jiaf410

### 第一部分 原文与翻译

**英文原标题：** Emergence of ST3390: A Novel Apigmented MRSA Clone From the CC5 Lineage.

> **英文摘要：**
> BACKGROUND: One of the most successful and widely-distributed hospital-associated lineages of MRSA is clonal complex 5 (CC5). These strains are known for widespread antibiotic resistance but less severe disease than CA-MRSA counterparts. Recently, CC5 descendant lineages have appeared globally with hypervirulent properties. Herein, we identify and characterize a rare and novel CC5 MRSA sequence type, ST3390. METHODS: We used whole genome sequencing, alongside phenotypic characterizations, genetic complementation, blood viability- and neutrophil-killing assays, and a murine model of sepsis to study the pathogenic capabilities of ST3390 strains. RESULTS: To date, there have only been 65 recorded instances of infection caused by ST3390 globally, with 36 of those occurring in Tampa (TPA-ST3390). Genomic analysis of strains identified numerous spa-types, with a t010 cluster found only in our strains. Exploration of AMR genes detected the presence of unique hybrid SCCmec types, with ∼90% of Tampa strains possessing components of SCCmecIa, SCCmecIIa, and/or SCCmecVIII. Phenotypically, all ST3390 strains lack the staphyloxanthin pigment, which is mediated by a conserved 6aa in frame deletion within the staphyloxanthin biosynthesis protein CrtN. TPA-ST3390 strains display high levels of cytotoxicity towards human neutrophils compared with other CC5 lineages and are also virulent in animal models of infection. CONCLUSIONS: This is the first study to characterize the pathogenicity and genomic architecture of the rare MRSA lineage ST3390. Our work provides a deeper understanding of the clonal expansion of CC5, and the wider diversification of Staphylococcus aureus isolates within patient populations.

> **中文摘要：**
> 背景：耐甲氧西林金黄色葡萄球菌（MRSA）最成功且分布最广泛的医院相关谱系之一是克隆复合物 5（CC5）。这些菌株以广泛的抗生素耐药性而闻名，但与社区获得性 MRSA（CA-MRSA）相比，引起的疾病严重程度较低。最近，全球范围内出现了具有高毒力特性的 CC5 后代谱系。在此，我们鉴定并表征了一种罕见的新型 CC5 MRSA 序列类型，即 ST3390。方法：我们利用全基因组测序，结合表型表征、遗传互补、血液活力和中性粒细胞杀伤实验，以及小鼠败血症模型，研究了 ST3390 菌株的致病能力。结果：迄今为止，全球范围内仅记录了 65 例由 ST3390 引起的感染实例，其中 36 例发生在坦帕（TPA-ST3390）。菌株的基因组分析鉴定了多种 spa 类型，其中 t010 簇仅见于我们的菌株。对抗菌素耐药（AMR）基因的探索检测到了独特的杂交 SCCmec 类型，约 90% 的坦帕菌株携带 SCCmecIa、SCCmecIIa 和/或 SCCmecVIII 的成分。在表型上，所有 ST3390 菌株均缺乏葡萄球菌黄素色素，这是由于葡萄球菌黄素生物合成蛋白 CrtN 中一个保守的 6 个氨基酸框内缺失所介导的。与其他 CC5 谱系相比，TPA-ST3390 菌株对人类中性粒细胞表现出高水平的细胞毒性，并且在动物感染模型中也具有毒力。结论：这是首项表征罕见 MRSA 谱系 ST3390 的致病性和基因组结构的研究。我们的工作为深入了解 CC5 的克隆扩张以及患者群体中金黄色葡萄球菌分离株更广泛的多样化提供了支持。

### 第二部分 AI 大师评价

该研究首次系统性地表征了新兴的 MRSA 谱系 ST3390，填补了 CC5 谱系高毒力进化研究的空白。通过整合全基因组测序、遗传互补及动物感染模型，研究揭示了该菌株独特的无色素表型（源于 CrtN 基因缺失）及复杂的杂交 SCCmec 基因组特征。研究证实了 ST3390 具有显著的中性粒细胞细胞毒性和致病性，为监测医院相关 MRSA 谱系向高毒力方向演化提供了重要的分子流行病学证据。

---

## 20. 2016-2023年科罗拉多州50岁及以上成年人中人类偏肺病毒、呼吸道合胞病毒及流感相关肺炎住院情况研究

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/40690544)
**期刊：** The Journal of infectious diseases
**PMID：** 40690544
**DOI：** 10.1093/infdis/jiaf381

### 第一部分 原文与翻译

**英文原标题：** Human Metapneumovirus-, Respiratory Syncytial Virus-, and Influenza-Associated Pneumonia Hospitalizations in Colorado Adults Aged ≥50 Years, 2016-2023.

> **英文摘要：**
> BACKGROUND: The study objectives were to identify the frequency and risk factors for intensive care unit (ICU) admission and mortality associated with respiratory syncytial virus (RSV), influenza, and human metapneumovirus (HMPV) pneumonia hospitalizations and to compare these rates with patients admitted with other acute respiratory infections (ARIs) caused by these viruses.
> 
> METHODS: This study identified hospitalization encounters of adults aged 50-88 years with RSV, influenza, and HMPV pneumonia between 2016 and 2023 in the Colorado Hospital Association database. Multivariate logistic regression was used to estimate the odds of ICU admission and mortality.
> 
> RESULTS: Of 2210 hospitalized patients with RSV pneumonia, 780 (35%) were admitted to ICU and 205 (9.3%) died. Similar proportions were observed for HMPV pneumonia (27.5% and 5.9%) and influenza pneumonia (32.5% and 7.6%) ICU admissions and mortality, respectively. Dementia had the highest odds for ICU admission in patients with RSV pneumonia (adjusted odds ratio [aOR], 4.2 [95% confidence interval {CI}, 1.34-13.18]); chronic pulmonary disease (CPD) for influenza pneumonia (aOR, 2.99 [95% CI, 2.45-3.66]), and chronic obstructive pulmonary disease (COPD) without asthma for HMPV pneumonia (aOR, 5.04 [95% CI, 2.92-8.7]). Increasing age was associated with increased mortality for RSV and influenza. CPD and COPD had >2-fold greater odds of mortality in patients with pneumonia for all 3 viruses. Increasing numbers of comorbidities significantly increased ICU admission and mortality in all 3 groups.
> 
> CONCLUSIONS: Pneumonia is a severe manifestation of ARI with RSV, influenza, and HMPV, with differing risk factors for ICU admission and mortality.

> **中文摘要：**
> 背景：本研究旨在确定与呼吸道合胞病毒（RSV）、流感和人类偏肺病毒（HMPV）肺炎住院相关的重症监护病房（ICU）入住率和死亡率的频率及其风险因素，并将这些比率与因这些病毒引起其他急性呼吸道感染（ARI）入院的患者进行比较。
> 
> 方法：本研究在科罗拉多州医院协会数据库中识别了2016年至2023年间50至88岁患有RSV、流感和HMPV肺炎的成年人住院病例。使用多变量逻辑回归来评估入住ICU和死亡的几率。
> 
> 结果：在2210名RSV肺炎住院患者中，780人（35%）入住ICU，205人（9.3%）死亡。HMPV肺炎（入住ICU率为27.5%，死亡率为5.9%）和流感肺炎（分别为32.5%和7.6%）也观察到了相似的比例。在RSV肺炎患者中，痴呆症的ICU入住几率最高（调整后优势比 [aOR] 为4.2 [95% 置信区间 {CI}, 1.34-13.18]）；流感肺炎患者为慢性肺部疾病（CPD）（aOR, 2.99 [95% CI, 2.45-3.66]）；而无哮喘的慢性阻塞性肺疾病（COPD）则是HMPV肺炎的最高风险因素（aOR, 5.04 [95% CI, 2.92-8.7]）。年龄增长与RSV和流感的死亡率增加相关。对于所有三种病毒，患有肺炎的患者中，CPD和COPD患者的死亡几率增加了2倍以上。在所有三组中，共病数量的增加显著增加了ICU入住率和死亡率。
> 
> 结论：肺炎是RSV、流感和HMPV引起的急性呼吸道感染的严重表现，且入住ICU和死亡的风险因素各不相同。

### 第二部分 AI 大师评价

这项基于科罗拉多州大样本数据库的观察性研究，系统地比较了中老年群体中三种主要呼吸道病毒肺炎的临床负担与预后。研究通过多变量分析，精准地识别了不同病原体肺炎入住ICU的特异性风险因素，如痴呆症与RSV、慢阻肺与HMPV的高度关联。其核心价值在于量化了病毒性肺炎导致的重症率，并强调了共病管理在降低高龄患者死亡风险中的关键作用，为呼吸道病毒感染的差异化临床决策提供了实证支持。

---

## 21. 疟疾住院患儿可溶性尿激酶型纤溶酶原激活物受体水平升高、器官功能障碍与死亡：将其用作风险分层工具的考量

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/40570199)
**期刊：** The Journal of infectious diseases
**PMID：** 40570199
**DOI：** 10.1093/infdis/jiaf327

### 第一部分 原文与翻译

**英文原标题：** Elevated Soluble Urokinase-Type Plasminogen Activator Receptor Levels, Organ Dysfunction, and Death in Children Hospitalized With Malaria: Considerations for Use as a Risk Stratification Tool.

> **英文摘要：**
> Soluble urokinase-type plasminogen activator receptor (suPAR) is an emerging critical illness biomarker. Circulating suPAR levels are elevated in severe malaria and are associated with mortality risk. The present study evaluated clinical predictors of elevated plasma suPAR (≥15 ng/mL). Elevated suPAR occurred in 22.1% of 1226 Ugandan children with severe malaria and was independently associated with severe acute kidney injury, hyperlactatemia, and coma, as well as biomarkers of immune and endothelial activation. An optimized clinical decision algorithm that prioritizes suPAR testing for children with clinical danger signs, including coma and kidney injury, could improve the identification of children at highest risk of death.

> **中文摘要：**
> 可溶性尿激酶型纤溶酶原激活物受体（suPAR）是一种新兴的危重症生物标志物。在重症疟疾中，循环 suPAR 水平升高且与死亡风险相关。本研究评估了血浆 suPAR 升高（≥15 ng/mL）的临床预测因子。在 1226 名患有重症疟疾的乌干达儿童中，22.1% 出现了 suPAR 升高，且该升高与重症急性肾损伤、高乳酸血症、昏迷以及免疫和内皮激活的生物标志物独立相关。一种针对具有昏迷和肾损伤等临床危险指征的儿童优先进行 suPAR 检测的优化临床决策算法，可提高对死亡风险最高的儿童的识别能力。

### 第二部分 AI 大师评价

本研究深入探讨了 suPAR 水平在重症疟疾患儿中的预后价值，证实其与器官功能障碍（尤其是肾损伤和昏迷）及高死亡风险紧密相关。通过对大规模临床队列的分析，研究明确了高浓度 suPAR 的独立预测意义，并提出了一种结合临床体征与生物标志物检测的阶梯式风险分层模型。这一创新算法不仅提升了对高危患儿识别的精准度，也为资源有限地区优化医疗资源配置、降低疟疾相关病死率提供了科学依据。

---

## 22. 美国传染病学会 2024 年 COVID-19 管理临床实践指南更新：用于暴露前预防的抗 SARS-CoV-2 中和抗体 Pemivibart

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/39471458)
**期刊：** Clinical infectious diseases : an official publication of the Infectious Diseases Society of America
**PMID：** 39471458
**DOI：** 10.1093/cid/ciae435

### 第一部分 原文与翻译

**英文原标题：** 2024 Clinical Practice Guideline Update by the Infectious Diseases Society of America on the Management of COVID-19: Anti-SARS-CoV-2 Neutralizing Antibody Pemivibart for Pre-exposure Prophylaxis.

> **英文摘要：**
> This article provides a focused update to the clinical practice guideline on the treatment and management of patients with coronavirus disease 2019, developed by the Infectious Diseases Society of America. The guideline panel presents a recommendation on the use of the anti-severe acute respiratory syndrome coronavirus 2 neutralizing antibody pemivibart as pre-exposure prophylaxis. The recommendation is based on evidence derived from a systematic review and adheres to a standardized methodology for rating the certainty of evidence and strength of recommendation according to the GRADE (Grading of Recommendations, Assessment, Development, and Evaluation) approach. Information on pemivibart is included in the U.S. Food and Drug Administration Emergency Use Authorization for this agent.

> **中文摘要：**
> 本文对美国传染病学会制定的 2019 冠状病毒病患者治疗和管理临床实践指南进行了专题更新。指南专家组针对使用抗严重急性呼吸系统综合症冠状病毒 2（SARS-CoV-2）中和抗体 Pemivibart 作为暴露前预防提出了建议。该建议基于通过系统评价获得的证据，并遵循 GRADE（推荐分级的评估、制定与评价）方法，对证据确定性和推荐强度进行分级的标准化方法。有关 Pemivibart 的信息已包含在 美国食品药品监督管理局（FDA）针对该药物的紧急使用授权中。

### 第二部分 AI 大师评价

该指南更新针对 COVID-19 的暴露前预防提供了及时的临床指导，重点评估了新型中和抗体 Pemivibart 的应用。研究采用了严谨的 GRADE 循证医学方法论，确保了推荐建议的科学性与权威性。其核心意义在于为免疫功能受损等高风险人群在现有疫苗保护之外提供了补充的预防策略。局限性在于该药物目前仍处于紧急使用授权阶段，其长期临床有效性及应对不断演变的新型变异株的有效性仍需更多实时监测数据支持。

---

速递结束，祝您工作愉快！